Immunitor LLC   Report issue

For profit Phase 2 Phase 3
Founded: Chachoengaso Thailand (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2010
NCT01222338
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Immunitor Inc. | Immunitor LLC | Immunitor USA Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 3)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Cholangiocarcinoma (Phase 2)

Endometriosis (Phase 2)

Fibroma (Phase 2)

Leiomyoma (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Neoplasms (Phase 3)

Myofibroma (Phase 2)

Myoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Tuberculosis (Phase 3)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 12